BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hyperprolactinemia might be related to weight gain, metabolic syndrome (MS), and insulin resistance (IR). Treatment with dopamine agonist (DA) has been shown to reduce body weight and improve metabolic parameters. The objectives of this study were to determine the prevalence of obesity, overweight, MS, and IR in patients with prolactinoma before and after therapy with DA and to evaluate the relation between prolactin (PRL), body weight, fat distribution, leptin levels, IR, and lipid profile before treatment. In addition, we investigated the correlation of the reduction in PRL levels with weight loss and metabolic profile improvement. Twenty‐two patients with prolactinoma completed 6 months of treatment with DA. These patients were submitted to clinical (BMI, waist circumference, blood pressure (BP)), laboratory evaluation (leptin, glucose, low‐density lipoprotein (LDL)‐cholesterol, and triglyceride (TG) levels) and abdominal computed tomography (CT) before and after treatment. The statistical analyses were done by nonparametric tests. At the beginning of the study, the prevalence of obesity, overweight, MS, and IR was 45, 27, 27, and 18%, respectively. After 6 months of treatment with DA, PRL levels normalized, but no significant difference in BMI was observed. However, there was a significant decrease on homeostasis model assessment of insulin resistance (HOMA IR) index, glucose, LDL‐cholesterol, and TG levels. This study suggests a possible involvement of prolactinoma on the prevalence of obesity. We should consider that DA may be effective on improving metabolic parameters, and we speculate that a period longer than 6 months of treatment is necessary to conclude whether this drug can interfere in the body weight of patients with prolactinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864 · cited 1×
“The possible physiopathological mechanisms involved in weight gain in patients with hyperprolactinemia are as follows: (i) reduction in dopaminergic tone (5,13,14); (ii) leptin resistance (5,15,16); (iii) decreased adiponectin levels (17); (iv) increased hypothalamic pressure; (18) and (v) hypogonadism (19).”
BackgroundCause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542 · cited 1×
“The prevalence of obesity is increasing worldwide and it is responsible for an increased morbidity and mortality, mainly due to cardiovascular disease and cancer (1).”
BackgroundGreenman, Y., Tordjman, K., & Stern, N. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00403.x · Cited by 227
Nilsson, L., Binart, N., Bohlooly-Y, M., Bramnert, M., Egecioglu, E., Kindblom, J., Kelly, P. A., Kopchick, J. J., Ormandy, C. J., Ling, C., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.04.026 · Cited by 191 · cited 1×
“The possible physiopathological mechanisms involved in weight gain in patients with hyperprolactinemia are as follows: (i) reduction in dopaminergic tone (5,13,14); (ii) leptin resistance (5,15,16); (iii) decreased adiponectin levels (17); (iv) increased hypothalamic pressure; (18) and (v) hypogonadism (19).”
Background
Cited by
Prolactin Promotes Adipose Tissue Fitness and Insulin Sensitivity in Obese Males
Ruiz-Herrera, X., de los Ríos, E. A., Díaz, J. M., Lerma-Alvarado, R. M., de la Escalera, L. M., López-Barrera, F., Lemini, M., Arnold, E., de la Escalera, G. M., Clapp, C., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1444 · Cited by 93
Inancli, S. S., Usluogullari, A., Ustu, Y., Caner, S., Tam, A. A., Ersoy, R., & Cakir, B. (2013) · Endocrine · doi:10.1007/s12020-012-9857-y · Cited by 59
Laway, B., Pala, N., Misgar, R., Shah, Z., Gojwari, T., & Dar, T. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176346 · Cited by 21
Metadata
- Authors
- Santos‐Silva, C. M., Barbosa, F. R. P., Lima, G. A. B., Warszawski, L., Fontes, R., Domingues, R. C., & Gadelha, M. R.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 19
- Issue
- 4
- Pages
- 800-805
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2147488395
- Cited by
- 183
- References
- 8
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.